



CLAIMS

1. A compound of Formula (I):



5 wherein,

ring E is a 5-membered non aromatic heterocyclic ring selected from



X, at each occurrence, is independently selected from -C(O)-, -CR₄R₅- and -NR-;

Y, at each occurrence, is independently selected from -C(O)- and -CR₄R₅-;

10 R is selected from alkyl, haloalkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, -C(O)NR₆R₇, -C(O)OR₆ and -C(O)R₆;

ring W is selected from aryl, heteroaryl, cycloalkyl and heterocyclyl;

R₁, which may be same or different at each occurrence, is independently selected from halo, cyano, nitro, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, heteroaryl, heterocyclyl, -S(O)_nR₆, -NR₆S(O)₂R₇, -NR₆(CR₈R₉)_nC(O)OR₆, -NR₆(CR₈R₉)_nC(O)R₆, -NR₆(CR₈R₉)_nC(O)NR₆R₇, -C(O)NR₆R₇, -C(O)(O)R₆, -C(O)R₆, -OC(O)R₆, and -OC(O)NR₆R₇;

15

R₂, which may be same or different at each occurrence, is independently selected

from hydrogen, halo, hydroxyl, cyano, nitro, alkyl, haloalkyl, alkenyl, alkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, cycloalkyl, cycloalkoxy, $-C(O)OR_6$, $-NR_6R_7$, $-C(O)R_6$, $-NHS(O)_2R_7$ and $-NHC(O)R_6$;

5 R_3 , which may be same or different at each occurrence, is independently selected from hydrogen, halo, hydroxyl, alkyl, alkoxy, haloalkyl, haloalkoxy, $-NR_6R_7$, $-NR_6S(O)_2R_7$, $-C(O)NR_6R_7$ and $-C(O)OR_6$;

R_4 and R_5 , which may be same or different at each occurrence, are independently selected from hydrogen, halo, $-OR_{10}$, alkyl, haloalkyl, hydroxyalkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, $-(CR_8R_9)_nC(O)NR_6R_7$, $-C(O)R_6$, and $-(CR_8R_9)_nC(O)OR_6$;

10 provided that, when any of R_4 or R_5 in Y is $-OR_{10}$ then R_{10} is not hydrogen; or


R_4 and R_5 , taken together with the carbon atom to which they are attached to, may form a substituted or unsubstituted 3- to 7- membered carbocyclic or heterocyclic ring; or

any one of R_4 and R_5 in X and any one of R_4 and R_5 in Y combined together, when they are attached to carbon atoms, may form a 4- to 7- membered substituted or unsubstituted
15 heterocyclic ring in order to give a bicyclic heterocyclic ring;

provided that

both of X and Y are not simultaneously $-C(O)-$;

ring D is selected from



20 Wherein, both A^1 and A^2 are C or N;

G is selected from S, NR_{12} and O;

L is $-C(O)NR_{11}-$ or $-NR_{11}C(O)-$;

R₁₁, at each occurrence, is independently selected from hydrogen, alkyl and aryl;

R₁₂ is selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl;

R₁₀ is selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl;

5 R₆ and R₇, which may be same or different at each occurrence, are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl; or R₆ and R₇, taken together with the nitrogen atom to which they are attached to, may form a substituted or unsubstituted 3- to 14- membered heterocyclic ring;

10 R₈ and R₉, which may be same or different at each occurrence, are independently selected from hydrogen, halo, alkyl and alkoxy; or R₈ and R₉, taken together with the carbon atom they are attached to, may form a 3- to 6- membered cyclic ring wherein the cyclic ring may be carbocyclic or heterocyclic;

n is an integer ranging from 0 to 2, both inclusive;


p is an integer ranging from 0 to 5, both inclusive;

q is an integer ranging from 1 to 4, both inclusive; and


15 wherein alkyl, haloalkyl, hydroxyalkyl, alkenyl, alkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, cycloalkyl, cycloalkoxy, aryl, heteroaryl, heterocyclyl, wherever they occur may optionally be substituted with one or more substituents independently selected from hydroxy, halo, cyano, nitro, oxo (=O), thio (=S), alkyl, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, heteroaryl, heterocyclic
20 ring, heterocyclylalkyl, heteroarylalkyl, -C(O)OR^x, -C(O)R^x, -C(S)R^x, -C(O)NR^xR^y, -NR^xC(O)NR^yR^z, -N(R^x)S(O)R^y, -N(R^x)S(O)₂R^y, -NR^xR^y, -NR^xC(O)R^y, -NR^xC(S)R^y, -NR^xC(S)NR^yR^z, -S(O)₂NR^xR^y, -OR^x, -OC(O)R^x, -OC(O)NR^xR^y, -R^xC(O)OR^y, -R^xC(O)NR^yR^z, -R^xC(O)R^y, -SR^x, and -S(O)₂R^x; wherein each occurrence of R^x, R^y and R^z are independently selected from hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl,
25 cycloalkyl, cycloalkenyl, heteroaryl, heterocyclic ring, heterocyclylalkyl ring and heteroarylalkyl;


or a pharmaceutically acceptable salt thereof or ~~stereoisomers~~ stereoisomers thereof.

2. The compound of claim 1 having the Formula (Ia):




or a pharmaceutically acceptable salt thereof;

- 5 wherein ring  is selected from Formula (i) to (iv)





ring W, ring D, R, R₁, R₂, R₃, R₄, R₅, R₁₀, 'p' and 'q' are as defined claim 1.

3. The compound of claim 1 having the Formula (Ib):




- 10 or a pharmaceutically acceptable salt thereof;

wherein ring  is selected from Formula (i) to (iv)





ring W, ring D, R, R₁, R₂, R₃, R₄, R₅, R₁₀, 'p' and 'q' are as defined in claim 1.

4. The compound of claim 1 having the Formula (Ic):




or a pharmaceutically acceptable salt thereof;

wherein ring  is selected from Formula (v) to (vii)





5 ring W, ring D, R, R₁, R₂, R₃, R₄, R₅, 'p' and 'q' are as defined in claim 1.

5. The compound of claim 1 having the Formula (Id):




or a pharmaceutically acceptable salt thereof;

wherein ring  is selected from Formula (v) to (vii)



ring W, ring D, R, R₁, R₂, R₃, R₄, R₅, 'p' and 'q' are as defined in claim 1.

6. The compound of claim 1, wherein ring E is non aromatic heterocyclic ring selected from



X, at each occurrence, is independently selected from -C(O)-, -CR₄R₅- and -NR-;

Y, at each occurrence, is independently selected from C(O) and -CR₄R₅;

R is selected from alkyl, haloalkyl, cycloalkyl, aryl and heteroaryl;

- 5 R₄ and R₅, which may be same or different at each occurrence, are independently selected from hydrogen, halo, OR₁₀, alkyl, haloalkyl, hydroxyalkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -(CR₈R₉)_nC(O)NR₆R₇, -C(O)R₆, and -(CR₈R₉)_nC(O)OR₆; or


R₄ and R₅, taken together with the carbon atom to which they are attached to, may form a substituted or unsubstituted 3- to 7- membered carbocyclic or heterocyclic ring; or

- 10 any one of R₄ and R₅ in X and any one of R₄ and R₅ in Y combined together, when they are attached to carbon atoms, may form a 4- to 7- membered substituted or unsubstituted heterocyclic ring in order to give a bicyclic heterocyclic ring; or

R₆, R₇, R₈ and R₉ are independently selected from hydrogen, substituted or unsubstituted alkyl and substituted or unsubstituted cycloalkyl; and

- 15 R₁₀ is selected from hydrogen, substituted or unsubstituted alkyl and substituted or unsubstituted cycloalkyl.

7. The compound of claim 1, wherein ring D is



wherein, both A¹ and A² are C or N;

- 20 G is NR₁₂; R₃ is as defined in claim 1;

'q' is 0, 1 or 2; and


R₁₂ is hydrogen or alkyl.

R₁₂ is selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl.

8. The compound of claim 1, wherein ring W is selected from aryl, heteroaryl and
5 cycloalkyl.

9. The compound of claim 1, wherein L is -C(O)NR₁₁- or -NR₁₁C(O)-; where R₁₁ is hydrogen or alkyl.

10. The compound of claim 1, wherein ring E is selected from:



10 ring W is aryl or heteroaryl;

R is alkyl; R₃ is hydrogen or alkyl; 'q' is 0 or 1;

R₁ is halo or alkyl; 'p' is 0, 1 or 2;

R₄ and R₅, which may be same or different at each occurrence, are independently
selected from hydrogen, alkyl, haloalkyl, hydroxyalkyl, cycloalkyl, -(CR₈R₉)_nC(O)NR₆R₇,
15 and -(CR₈R₉)_nC(O)OR₆; 'n' is 0 or 1;

R₄ and R₅, taken together with the carbon atom to which they are attached to, may
form a substituted or unsubstituted 3- to 7- membered carbocyclic or heterocyclic ring; or

L is -C(O)NR₁₁- or -NR₁₁C(O)-;

R₁₁ is selected from hydrogen or alkyl;

R₂ is independently selected from hydrogen, halo, hydroalkyl, alkyl, haloalkyl, alkoxy, haloalkoxy, (C₃-C₁₂)cycloalkoxy, -C(O)OR₆, -NR₆R₇, -C(O)R₆, and -NHC(O)R₆; 'n' is 0, or 1 or 2; and

R₆, R₇, R₈ and R₉ are independently hydrogen or alkyl; and

5 ring D is defined in claim 1;

or a pharmaceutically acceptable salt thereof or stereoisomers thereof.

11. The compound of claim 1, which is selected from:

N-(5-(5-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazine-2-yl)-2,6-difluorobenzamide,

10 *N*-(5-(5-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)-4-methyl-1,2,3-thiadiazole-5-carboxamide,

N-(5'-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2'-methyl-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,

15 *N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-ethylphenyl)pyrazin-2-yl)-2,6-difluorobenzamide,

N-(5'-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2'-ethyl-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,

N-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-isopropylphenyl)pyrazin-2-yl)-2,6-difluorobenzamide,

20 *N*-(5'-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2'-isopropyl-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,

N-(2'-(tert-butyl)-5'-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,

25 *N*-(2'-chloro-5'-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,

N-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-fluorophenyl)pyrazin-2-yl)-2,6-difluorobenzamide,

N-(5'-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2'-fluoro-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,

N-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methoxyphenyl)pyrazin-2-yl)-2,6-difluorobenzamide,

5 *N*-(5'-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2'-methoxy-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,

N-(5'-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2'-methoxy-[1,1'-biphenyl]-4-yl)-4-methyl-1,2,3-thiadiazole-5-carboxamide,

10 *N*-(2'-acetamido-5'-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,

N-(5-(3-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)phenyl)pyrazin-2-yl)-2,6-difluorobenzamide,

N-(3'-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,

15 2,6-difluoro-*N*-(5-(5-(4-methoxy-5,5-dimethyl-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)benzamide,

2,6-Difluoro-*N*-(5'-(4-methoxy-5,5-dimethyl-4,5-dihydroisoxazol-3-yl)-2'-methyl-[1,1'-biphenyl]-4-yl)benzamide,

20 *N*-(4'-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2'-methyl-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,

N-(5-(4-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)-2,6-difluorobenzamide,

N-(5-(3-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)-2,6-difluorobenzamide,

25 *N*-(3'-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2'-methyl-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,

N-(3'-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2'-methoxy-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,

N-(5-(5-(4-Acetyl-5,5-dimethyl-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-methylphenyl)pyrazin-2-yl)-2,6-difluorobenzamide,

2,6-Difluoro-*N*-(2'-methyl-5'-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-4-yl)benzamide,

5 *N*-(5'-(4-Ethyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2'-methyl-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,

2,6-Difluoro-*N*-(2'-methyl-5'-(5-oxo-4-propyl-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-4-yl)benzamide,

10 *N*-(2'-Ethyl-5'-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,

2-Chloro-*N*-(2'-ethyl-5'-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-4-yl)-6-fluorobenzamide,

N-(2'-Ethyl-5'-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-4-yl)-2-fluoro-6-methylbenzamide,

15 *N*-(2'-Ethyl-5'-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-4-yl)-4-methyl-1,2,3-thiadiazole-5-carboxamide,

2,6-Difluoro-*N*-(2'-methoxy-5'-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-4-yl)benzamide,

20 2-Chloro-6-fluoro-*N*-(2'-methoxy-5'-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-4-yl)benzamide,

2-Fluoro-*N*-(2'-methoxy-5'-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-4-yl)-6-methylbenzamide,

4-Ethyl-*N*-(2'-methoxy-5'-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-4-yl)benzamide,

25 *N*-(2'-(Difluoromethoxy)-5'-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,

N-(2'-(Difluoromethoxy)-5'-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-4-yl)-4-methyl-1,2,3-thiadiazole-5-carboxamide,

- N*-(2'-Chloro-5'-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,
- N*-(2'-Chloro-5'-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-4-yl)-4-methyl-1,2,3-thiadiazole-5-carboxamide,
- 5 2,6-Difluoro-*N*-(2'-methyl-3'-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-4-yl)benzamide,
- 2-Chloro-6-fluoro-*N*-(2'-methyl-3'-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-4-yl)benzamide,
- 10 4-Methyl-*N*-(2'-methyl-3'-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-4-yl)-1,2,3-thiadiazole-5-carboxamide,
- N*-(2'-ethyl-3'-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-4-yl)-4-methyl-1,2,3-thiadiazole-5-carboxamide,
- N*-(2'-ethyl-3'-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,
- 15 *N*-(5-(5,5-Dimethyl-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)-2,6-difluorobenzamide,
- Methyl 3-(3-(5-(2,6-difluorobenzamido)pyrazin-2-yl)-4-methylphenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate,
- Methyl-3-(4'-(2,6-difluorobenzamido)-6-methyl-[1,1'-biphenyl]-3-yl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate,
- 20 2,6-Difluoro-*N*-(2'-methyl-5'-(1-oxa-2-azaspiro[4.4]non-2-en-3-yl)-[1,1'-biphenyl]-4-yl)benzamide,
- 2,6-Difluoro-*N*-(5-(2-methyl-5-(1-oxa-2-azaspiro[4.4]non-2-en-3-yl)phenyl)pyrazin-2-yl)benzamide,
- 25 *N*-(5-(5-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-2-methylphenyl)pyrazine-2-yl)-2,6-difluorobenzamide,
- N*-(5'-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-2'-methyl-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,

2,6-Difluoro-*N*-(2'-methyl-5'-(4-methyl-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)benzamide,

4-Methyl-*N*-(2'-methyl-5'-(4-methyl-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)-1,2,3-thiadiazole-5-carboxamide,

5 Ethyl 3-(4'-(2,6-difluorobenzamido)-6-methyl-[1,1'-biphenyl]-3-yl)-4,4-dimethyl-4,5-dihydroisoxazole-5-carboxylate,

N-(5-(5-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazine-2-yl)-2-fluorobenzamide,

10 *N*-(5-(5-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazine-2-yl)-2,4-difluorobenzamide,

N-(5-(5-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazine-2-yl)-2,5-difluorobenzamide,

N-(5-(5-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazine-2-yl)-2,3-difluorobenzamide,

15 *N*-(5-(5-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazine-2-yl)-4-fluorobenzamide,

N-(5-(5-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazine-2-yl)-2,4,5-trifluorobenzamide,

20 *N*-(5-(5-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazine-2-yl)-2,3-dimethylbenzamide,

N-(5-(5-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazine-2-yl)-4-trifluoromethylbenzamide,

N-(5-(5-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazine-2-yl)-4-fluoro-3-methylbenzamide,

25 *N*-(5-(5-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazine-2-yl)-2-methylbenzamide,

N-(5-(5-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazine-2-yl)-3-fluoro-5-trifluoromethylbenzamide,

Methyl-3-(4'-(2,6-difluorobenzamido)-6-methyl-[1,1'-biphenyl]-3-yl)-5-(2-methoxy-2-oxoethyl)-4,5-dihydroisoxazole-5-carboxylate,

Methyl 3-(3-(5-(2,6-difluorobenzamido)pyrazin-2-yl)-4-methylphenyl)-5-(2-methoxy-2-oxoethyl)-4,5-dihydroisoxazole-5-carboxylate,

5 2,6-Difluoro-*N*-(5-(2-methyl-5-(4-oxo-3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazol-3-yl)phenyl)pyrazin-2-yl)benzamide,

2-Chloro-*N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)benzamide,

10 *N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)-2-fluoro-6-(trifluoromethyl)benzamide,

2-Chloro-*N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)-6-fluorobenzamide,

N-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)-2-methoxybenzamide,

15 *N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)cyclohexanecarboxamide,

N-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)cyclopentanecarboxamide,

20 *N*-(5-(2-(*tert*-butyl)-5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)phenyl)pyrazin-2-yl)-2,6-difluorobenzamide,

N-(5-(3-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methoxyphenyl)pyrazin-2-yl)-2,6-difluorobenzamide,

N-(5-(2-chloro-5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)phenyl)pyrazin-2-yl)-2,6-difluorobenzamide,

25 2,6-Difluoro-*N*-(5-(2-methyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl)pyrazin-2-yl)benzamide,

N-(5-(5-(4-Ethyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-methylphenyl)pyrazin-2-yl)-2,6-difluorobenzamide,

- 2,6-Difluoro-*N*-(5-(2-methyl-5-(5-oxo-4-propyl-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl)pyrazin-2-yl)benzamide,
- N*-(5-(2-Ethyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl)pyrazin-2-yl)-2,6-difluorobenzamide,
- 5 2-Chloro-*N*-(5-(2-ethyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl)pyrazin-2-yl)-6-fluorobenzamide,
- N*-(5-(2-Ethyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl)pyrazin-2-yl)-2-fluoro-6-methylbenzamide,
- 10 2,6-Difluoro-*N*-(5-(2-methoxy-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl)pyrazin-2-yl)benzamide,
- 2,6-Difluoro-*N*-(5-(2-fluoro-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl)pyrazin-2-yl)benzamide,
- N*-(5-(2-(difluoromethoxy)-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl)pyrazin-2-yl)-2,6-difluorobenzamide,
- 15 *N*-(5-(2-ethyl-3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl)pyrazin-2-yl)-2,6-difluorobenzamide,
- N*-(5-(5-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)picolinamide,
- N*-(5-(5-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)nicotinamide,
- 20 *N*-(5-(5-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)isonicotinamide,
- N*-(5-(5-(5,5-Dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)-2-methylnicotinamide,
- 25 6-Chloro-*N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)nicotinamide,
- 6-Chloro-*N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)isonicotinamide,

- 3,5-Dichloro-*N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)isonicotinamide,
- 4-Chloro-*N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)nicotinamide,
- 5 *N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)-6-methylnicotinamide,
- 5-Chloro-*N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)nicotinamide,
- 10 *N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)-3-fluoroisonicotinamide,
- N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)-5-fluoronicotinamide,
- N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)-2-fluoronicotinamide,
- 15 2-Chloro-*N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)isonicotinamide,
- 2-Chloro-*N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)-6-methylisonicotinamide,
- 20 *N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)-2-fluoroisonicotinamide,
- N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)-2-methylnicotinamide,
- N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)-3,5-difluoroisonicotinamide,
- 25 *N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)-3-methylisonicotinamide,
- N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methoxyphenyl)pyrazin-2-yl)-3,5-difluoroisonicotinamide,

- N*-(5-(2-ethyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl)pyrazin-2-yl)-3,5-difluoroisonicotinamide,
- 3,5-Difluoro-*N*-(5-(2-fluoro-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl)pyrazin-2-yl)isonicotinamide,
- 5 *N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)benzofuran-2-carboxamide,
- 2,6-Difluoro-*N*-(5-(2-methyl-5-(4-oxo-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)phenyl)pyrazin-2-yl)benzamide,
- 10 *N*-(2,6-Difluorophenyl)-5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazine-2-carboxamide,
- 4-(2,6-Difluorobenzamido)-3'-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-[1,1'-biphenyl]-2-carboxylic acid,
- N*-(5'-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2'-hydroxy-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,
- 15 *N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-hydroxyphenyl)pyrazin-2-yl)-2,6-difluorobenzamide,
- N*-(5'-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2'-isopropoxy-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,
- 20 *N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-isopropoxyphenyl)pyrazin-2-yl)-2,6-difluorobenzamide,
- N*-(5'-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2'-isobutoxy-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,
- N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-isobutoxyphenyl)pyrazin-2-yl)-2,6-difluorobenzamide,
- 25 *N*-(5'-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2'-ethoxy-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,
- N*-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-ethoxyphenyl)pyrazin-2-yl)-2,6-difluorobenzamide,

- N*-(5'-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2'-propoxy-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,
- N*-(2'-(allyloxy)-5'-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,
- 5 *N*-(2'-(cyclopentyloxy)-5'-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,
- N*-(2'-amino-5'-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,
- 10 *N*-(5'-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2'-(methylamino)-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,
- N*-(5'-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2'-(dimethylamino)-[1,1'-biphenyl]-4-yl)-2,6-difluorobenzamide,
- (*R/S*)-*N*-(5-(5-(5,5-Dimethyl-4-hydroxy-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazine-2-yl)-2,6-difluorobenzamide,
- 15 *N*-(5-(2-Methyl-3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl)pyrazin-2-yl)-1,2,3,4-tetrahydronaphthalene-2-carboxamide
- 3-(4'-(2,6-Difluorobenzamido)-6-methyl-[1,1'-biphenyl]-3-yl)-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid,
- 20 3-(3-(5-(2,6-difluorobenzamido)pyrazin-2-yl)-4-methylphenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid,
- 5-Carboxymethyl-3-(4'-(2,6-difluorobenzamido)-6-methyl-[1,1'-biphenyl]-3-yl)-4,5-dihydroisoxazole-5-carboxylic acid,
- 5-(Carboxymethyl)-3-(3-(5-(2,6-difluorobenzamido)pyrazin-2-yl)-4-methylphenyl)-4,5-dihydroisoxazole-5-carboxylic acid,
- 25 2,6-Difluoro-*N*-(5'-(5-(hydroxymethyl)-5-methyl-4,5-dihydroisoxazol-3-yl)-2'-methyl-[1,1'-biphenyl]-4-yl)benzamide,
- 2,6-Difluoro-*N*-(5-(5-(5-(hydroxymethyl)-5-methyl-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)benzamide,

2,6-Difluoro-*N*-(5'-(5-(2-hydroxyethyl)-5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-2'-methyl-[1,1'-biphenyl]-4-yl)benzamide,

N-(5-(5-(5,5-bis(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)-2,6-difluorobenzamide,

5 *N*-Cyclopropyl-3-(4'-(2,6-difluorobenzamido)-6-methyl-[1,1'-biphenyl]-3-yl)-5-methyl-4,5-dihydroisoxazole-5-carboxamide,

3-(4'-(2,6-difluorobenzamido)-6-methyl-[1,1'-biphenyl]-3-yl)-5-methyl-4,5-dihydroisoxazole-5-carboxamide,

10 3-(3-(5-(2,6-Difluorobenzamido)pyrazin-2-yl)-4-methylphenyl)-*N*,5-dimethyl-4,5-dihydroisoxazole-5-carboxamide,

3-(4'-(2,6-Difluorobenzamido)-6-methyl-[1,1'-biphenyl]-3-yl)-*N*,*N*,5-trimethyl-4,5-dihydroisoxazole-5-carboxamide

N-Cyclopropyl-3-(3-(5-(2,6-difluorobenzamido)pyrazin-2-yl)-4-methylphenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxamide,

15 2,6-Difluoro-*N*-(2'-methyl-5'-(5-methyl-5-(4-methylpiperazine-1-carbonyl)-4,5-dihydroisoxazol-3-yl)-[1,1'-biphenyl]-4-yl)benzamide,

2,6-Difluoro-*N*-(5-(2-methyl-5-(5-methyl-5-(4-methylpiperazine-1-carbonyl)-4,5-dihydroisoxazol-3-yl)phenyl)pyrazin-2-yl)benzamide,

20 5-(2-Amino-2-oxoethyl)-3-(4'-(2,6-difluorobenzamido)-6-methyl-[1,1'-biphenyl]-3-yl)-4,5-dihydroisoxazole-5-carboxamide,

3-(4'-(2,6-difluorobenzamido)-6-methyl-[1,1'-biphenyl]-3-yl)-*N*-methyl-5-(2-(methylamino)-2-oxoethyl)-4,5-dihydroisoxazole-5-carboxamide,

N-(2,6-difluorophenyl)-5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)-1-methyl-1H-pyrrole-2-carboxamide,

25 *N*-(2,6-difluorophenyl)-5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methoxyphenyl)-1-methyl-1H-pyrrole-2-carboxamide, and

N-(2,6-difluorophenyl)-5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-ethylphenyl)-1-methyl-1H-pyrrole-2-carboxamide,

or pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising one or more compounds of Formula (I) according to claim 1, and one or more pharmaceutically acceptable excipients.

13. A method of treating, preventing, managing and/or lessening diseases or disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel in a subject in need thereof wherein the method comprises administering to
5 the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

14. A compound of any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof for use in the treatment, prevention or management of diseases or disorders,
10 syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel.

15. Use of a compound of any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof for preparation of a medicament for the treatment, prevention or management of diseases or disorders, syndromes or conditions associated with the modulation of calcium
15 release activated calcium (CRAC) Channel


16. The method of claim 13, wherein the diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel are selected from the group consisting of inflammatory diseases, autoimmune diseases, allergic disorders, organ transplant, cancer and cardiovascular disorders.

20 17. The method of claim 13, wherein the disease is rheumatoid arthritis, multiple sclerosis and psoriasis.


18. The method of claim 13, wherein the disease is allergic disorders selected from asthma, chronic obstructive pulmonary disorder (COPD) or respiratory disorders.

19. The method of claim 14, wherein inflammatory diseases are selected from rheumatoid
25 arthritis, osteoarthritis, ankylosing spondylitis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), inflammatory bowel diseases, pancreatitis, peripheral neuropathy, multiple sclerosis (MS) and inflammation associated with cancer.

20. A process for the preparation of a compound of Formula (I):




comprising reacting a compound of Formula (1) with a compound of Formula (2)



5 wherein X' is halo;

ring E is a 5-membered non aromatic heterocyclic ring selected from



X, at each occurrence, is independently selected from -C(O)-, -CR₄R₅- and -NR-;

Y, at each occurrence, is independently selected from C(O) and -CR₄R₅-;

10 R is selected from alkyl, haloalkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, C(O)NR₆R₇, -C(O)OR₆ and -C(O)R₆;

ring W is selected from aryl, heteroaryl, cycloalkyl and heterocyclyl;

15 R₁, which may be same or different at each occurrence, is independently selected from halo, cyano, nitro, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, heteroaryl, heterocyclyl, -S(O)_nR₆, -NR₆S(O)₂R₇, -NR₆(CR₈R₉)_nC(O)OR₆, -NR₆(CR₈R₉)_nC(O)R₆, -NR₆(CR₈R₉)_nC(O)NR₆R₇, -C(O)NR₆R₇, -C(O)(O)R₆, -C(O)R₆, -OC(O)R₆, and -OC(O)NR₆R₇;

R₂, which may be same or different at each occurrence, is independently selected

from hydrogen, halo, hydroxyl, cyano, nitro, alkyl, haloalkyl, alkenyl, alkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, cycloalkyl, cycloalkoxy, $-C(O)OR_6$, $-NR_6R_7$, $-C(O)R_6$, $-NHS(O)_2R_7$ and $-NHC(O)R_6$;

5 R_3 , which may be same or different at each occurrence, is independently selected from hydrogen, halo, hydroxyl, alkyl, alkoxy, haloalkyl, haloalkoxy, $-NR_6R_7$, $-NR_6S(O)_2R_7$, $-C(O)NR_6R_7$ and $-C(O)OR_6$;

R_4 and R_5 , which may be same or different at each occurrence, are independently selected from hydrogen, halo, OR_{10} , alkyl, haloalkyl, hydroxyalkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, $-(CR_8R_9)_nC(O)NR_6R_7$, $-C(O)R_6$, and $-(CR_8R_9)_nC(O)OR_6$; or


10 when any of R_4 or R_5 in Y is OR_{10} then R_{10} is not hydrogen;

R_4 and R_5 , taken together with the carbon atom to which they are attached to, may form a substituted or unsubstituted 3- to 7- membered carbocyclic or heterocyclic ring; or

any one of R_4 and R_5 in X and any one of R_4 and R_5 in Y combined together, when they are attached to carbon atoms, may form a 4- to 7- membered substituted or unsubstituted
15 heterocyclic ring in order to give a bicyclic heterocyclic ring;

provided that both of X and Y are not simultaneously $-C(O)-$;

ring D is selected from



Wherein, both A^1 and A^2 are C or N;

20 G is selected from S , NR_{12} and O ; L is $-C(O)NR_{11}-$ or $-NR_{11}C(O)-$;

R_{11} , at each occurrence, is independently selected from hydrogen, alkyl and aryl;

R_{12} is selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl;

R₁₀ is selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl;

R₆ and R₇, which may be same or different at each occurrence, are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl; or R₆ and R₇, taken together with the nitrogen atom to which they are attached to, may form a substituted
5 or unsubstituted 3- to 14- membered heterocyclic ring;

R₈ and R₉, which may be same or different at each occurrence, are independently selected from hydrogen, halo, alkyl and alkoxy; or R₈ and R₉, taken together with the carbon atom they are attached to, may form a 3- to 6- membered cyclic ring wherein the cyclic ring may be carbocyclic or heterocyclic;

10 n is an integer ranging from 0 to 2, both inclusive;

p is an integer ranging from 0 to 5, both inclusive; and

q is an integer ranging from 1 to 4, both inclusive;

in presence of a catalyst selected from Pd(PPh₃)₂Cl₂, Pd₂dba₃, Pd(PPh₃)₄ or Pd(OAc)₂ or a mixture thereof; a ligand selected from BINAP, xanthophos or triphenylphosphine or a mixture thereof and a base.
15